Terumo Europe’s Post

Continuing to promote innovation across specialties!

At Aliro Consulting we believe that regionalizing joint venture (JV) investments is essential for maximizing ROI. By not limiting our focus to Northern technologies and instead supporting startups and R&D in Africa, Asia, and Latin America (LATAM), we can tap into diverse and emerging markets. This approach allows us to leverage unique regional strengths, foster innovation across different cultural contexts, and create sustainable growth opportunities. Supporting a wider range of regions enhances our ability to drive impactful and inclusive economic development while ensuring high-value returns for our clients. #Investment #Innovation #GlobalGrowth #EmergingMarkets #SustainableGrowth #InclusiveDevelopment #HighROI #RegionalInvestment

#Terumo today announced that it has established “Terumo Ventures”, a Corporate Venture Capital (CVC) organization responsible for leading the group’s venture investment, as a department within Terumo Americas Holding, Inc. Terumo Ventures operates in global innovation hubs around the globe, such as Massachusetts and California in the US, and invests US$ 75 million over the next five years in early-stage companies primarily in the field of cardiovascular disease treatment, chronic disease treatment, blood and cell technologies, and digital technologies. This will enable Terumo to enhance its access to innovative technologies and business ideas from start-ups, promote open innovation. Terumo has built relationship with Medtech start-ups by investing in venture capital funds in the US since 2013. With the establishment of the CVC, the company will further increase its agility to identify, evaluate, and execute venture investment, while accelerating the speed of acquiring cutting-edge technologies and developing a robust M&A target pipeline for future growth. ✅Press Release: https://lnkd.in/eYHHa2wb ✅Apply from: https://lnkd.in/eHS4TfVp   #TerumoVentures #innovation #Medtech #CVC #venturecapital #startups #technology

Neuspera Medical Inc.'s $23m series D raise earlier this week tips the total raised in #NeuroTech in 2024 to over $0.5billion! Here's the investors who've contributed so far this year: 8VC Action Potential Venture Capital Advent Life Sciences Ally Bridge Group Alzheimer's Drug Discovery Foundation Angelini Ventures Aperture Venture Partners Aphelion Capital Arboretum Ventures Asahi Kasei Avestria Ventures B Capital British Patient Capital Decheng Capital Dolby Family Ventures Endeavour Vision EQT Life Sciences Fountain Healthcare Partners FoundersX Ventures F-Prime Capital Gilde Healthcare Hatteras Venture Partners IAG Capital Partners INKEF Capital Intuitive Ventures JobsOhio Growth Capital Fund KdT Ventures Lightstone Ventures Longitude Capital Medtronic Morningside MVM Partners New Enterprise Associates (NEA) Northern Gritstone Novo Holdings Olympus innovation Ventures Oxford Science Enterprises Perceptive Advisors Pura Vida re.Mind Capital Satori Neuro Sectoral Asset Management ShangBay Capital Sofinnova Partners’ Crossover Fund Starbloom Tonkawa Treo Ventures Vensana Capital Vertex Ventures HC Viking Global Investors Voima Ventures Windham Capital Partners WSGR I would have tagged them all if I could but LinkedIn wouldn't let me. Nonetheless, a great canvassing list for any NeuroTech start-ups looking to raise capital.

📣 Want to know more about how we work to bring discoveries to lives at Lundbeckfonden BioCapital? 🔬🤝💊 Last week at Nordic Life Science Days, I caught up with Natasha Bank from BioStock - Connecting Innovation and Capital for a chat about our strategy for early stage investments. Lundbeckfonden / Lundbeck Foundation #venturecapital #lifescience #biotech #danskbiotek

💸Earlybird Venture Capital, a German venture capital firm, has announced the closure of a €173 million fund dedicated to healthtech. -- 👉This second fund of its kind from Earlybird aims to invest in startups within the biopharma, medtech, and digital health sectors. 👉 The fund will allocate about half of its resources to biopharma startups. The remaining funds will be split between medtech and digital health initiatives. This strategic investment underscores Earlybird’s commitment to exploiting the “unprecedented opportunity” in biopharma, according to principal Dr. Christoph Massner. Read the full article below👇 ⭐ PL Talents GmbH is your number one recruitment solution in tech in Germany. #venturecapital #fund #healthcare #technews #germany #pltalents

Kurma Partners, an asset manager focused on improving human health, secures €140 million in first close of mew €250 million Biofund IV, successfully completing the first closing of Biofund IV. Kurma aims to have raised a total of EUR 250 million in its newest and largest venture capital investment fund to date by the final closing in 2025. Biofund IV targets 16 to 20 new investments, of which the first three have been made. Like its predecessors, Biofund IV will be dedicated to companies developing innovative therapeutics, aiming for a balanced, risk-managed strategy, with investments for company creation as well as in established venture-stage companies. Kurma remains thematically agnostic and will continue to opportunistically pursue the forefront of innovation, to identify and create future industry trends. Daniel OLIVE, Olivier MILLET, Andrew Nash, Rémi Droller Read more - https://lnkd.in/gbZRhxsx To share your startup story write us on - contact@startuprise.co.uk #kurmapartner #new #funding #startup #fundraising

Venture capitals can help drive drug development, particularly for startups and early-stage biotechs. 💸 As most focus on raising funds to expand research and development, some play a significant role in launching life science companies and bringing their products to the clinic. 🏥 They can recruit expertise, form strategic alliances, in efforts to move drug candidates to the clinic, hoping they eventually hit the market. 🚀 Labiotech spoke to Johan Kördel, Managing Partner at Sound Bioventures and Stewart Dixon, Founder and Managing Partner of VentureDNA, to discuss the role of VCs in building biotechs and accelerating clinical progress. 📈 Read our latest article to find out how VCs can play a major role in the development of early-stage biotechs! 👇 https://lnkd.in/dRiC9Seq #venturecapital #biotechstartups #drugdevelopment #lifesciences #startupfunding #earlystagebiotech #clinicaldevelopment #strategicalliances #biotechinvestment

Many people, including most venture capitalists, believe that success in #biopharma venture capital, both for individuals & firms, depends on the ability to make successful investments. Good investments are necessary but not sufficient. No one is in the early-stage bio-venture business who does not at heart want to help patients and alleviate suffering. Most see themselves as drug developers, but ultimately a venture capitalist is judged by the returns he provides his investors. Being a biopharma venture capitalist is, indeed, very hard. #biotechnology #lifesciences #startup #innovation

VitruvianMD is pleased to share that Verge HealthTech Fund, an existing investor, has opted to increase their investment in our company. This decision reflects an ongoing confidence in our mission and progress, underscoring Verge HealthTech Fund's commitment to our shared goals and vision. VitruvianMD values the continued support, and this additional investment will provide us with the resources necessary to continue our growth trajectory and advance our objectives in the healthcare technology sector. Stay tuned for further updates on our progress and development as we revolutionise healthcare through our AI-powered technology. #healthtech #startups #investor #healthtechfund #vergehealthtechfund #vitruvianMD #AItechnology #medicalAI